Gefapixant, sold under the brand name Lyfnua, is a medication used to treat chronic (long-term) cough. It acts as an antagonist of the P2RX3 receptor.

11 сент. 2023 г. · Gefapixant (45 mg orally twice daily) led to modest improvements in cough frequency, cough severity, and cough-specific quality of life but increased taste- ...

Gefapixant is a novel antagonist of the P2X3 receptor that works to reduce the cough reflex in patients with chronic cough.

Gefapixant is a selective P2X3 receptor antagonist in Phase 3 clinical trials that has shown efficacy for the treatment of cough responses (McGarvey et al., ...

10 окт. 2023 г. · Lyfnua is a medicine used to treat adults with chronic (long-term) cough which is unexplained or for which other treatments have not worked.

20 дек. 2023 г. · The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck's New Drug Application (NDA) for gefapixant.

CONCLUSIONS: In patient with chronic cough, gefapixant exhibits favorable anti-tussive outcomes by improving the cough frequency, severity, and quality of life.

5 мар. 2022 г. · The gefapixant 45 mg twice per day dose showed clinically meaningful reduction in cough frequency that was significantly superior to placebo.

Gefapixant, an antagonist for both P2X2/3 and P2X3 receptors, not only suppresses cough response but also causes dysgeusia in many patients.

In this study, a single dose of gefapixant 100 mg demonstrated a significant reduction in objective cough frequency and positive improvements in patient- ...